WuXi AppTec– tag –
-
WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development
PR Newswire China Overview WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) researc... -
Transcenta Therapeutics and WuXi Biologics Forge Strategic Alliance to Expedite Commercialization of HiCB Continuous Bioprocessing Technologies
BioSpace USA Overview Transcenta Therapeutics and WuXi Biologics have entered a strategic collaboration to accelerate the commercialization and deployment of Transcenta's proprietary High-Intensity Continuous Bioprocessing (HiCB) platfor... -
WuXi Biologics Breaks Ground on $1.4 Billion CRDMO Center in Singapore, Boosting Global Manufacturing Capacity by 120,000 Liters
EDB Singapore China Overview WuXi Biologics has broken ground on a new $1.4 billion Contract Research, Development, and Manufacturing Organization (CRDMO) center in Singapore's Tuas Biomedical Park. This massive investment will add 120,0... -
RayzeBio to Invest $173 Million in Radiopharmaceutical Manufacturing Plant to Accelerate Production Expansion
Fierce Biotech USA Overview RayzeBio announced plans to invest $173 million in the construction of a new radiopharmaceutical manufacturing plant, significantly expanding its production capacity. This substantial investment aims to meet t... -
WuXi Biologics Reports 18.4% H1 2026 Revenue Growth and 300 IND Application Capacity Annually, Driven by Low-Cost Strategy
Seeking Alpha China Overview WuXi Biologics announced robust financial results for H1 2026, with revenue increasing by 18.4%, primarily driven by demand for investigational drugs and multi-specific antibodies. The company has expanded it... -
Continuous Upstream Bioprocessing Gains Traction, WuXi Biologics Pioneers Fully Automated Perfusion Platform for Enhanced Productivity
Pharma Manufacturing USA Overview Continuous upstream bioprocessing, especially perfusion culture, is significantly enhancing productivity and consistency in biomanufacturing. CDMOs are increasing investments in continuous bioprocessing ... -
WuXi XDC Reports $550.4M H1 Revenue (37% YoY Growth) and Reaffirms $1.2B Investment in ADC Manufacturing Capacity by 2030
Fierce Biotech China Overview WuXi XDC, the ADC-focused subsidiary of WuXi Bio, reported a significant 37% year-over-year revenue increase to RMB 3.7 billion (approximately $550.4 million) in the first half of 2026. The company also reaf... -
Perfusion Cell Culture Patents 2026: Top 5 Assignees Hold 79.2% Share, Hardware and Cell Line Engineering Dominate Claims
Patsnap Germany Overview A patent analysis based on mid-2026 data reveals that 79.2% of patent activity in perfusion and intensified cell culture technologies is concentrated among the top five assignees. These patents primarily cover ha... -
Perfusion Bioreactor Adoption Doubles to 65.8% Since 2016, Accelerating Shift to Continuous Biomanufacturing
synbio.intel USA Overview A BioPlan Associates survey from August 2026 reveals that single-use perfusion equipment usage has doubled to 65.8% across all production stages since 2016, indicating an accelerating shift towards continuous bi... -
Market Report: Global Single-Use Bioreactor Market to Surge, Thermo Fisher and AGC Biologics Expand Capacity
GlobeNewswire Global Overview This article summarizes the market research report "Global Single-use Bioreactors Market Forecast to Surge from USD 3.61 Billion in 2025 to USD 15.11 Billion by 2034." The global single-use bioreactors marke...
